Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Sartorius Stedim Biotech SA
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Sartorius Stedim Biotech SA
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Pre-Tax Income
€236m
CAGR 3-Years
-29%
CAGR 5-Years
-6%
CAGR 10-Years
9%
Pcas SA
PAR:PCA
Pre-Tax Income
€12.5m
CAGR 3-Years
N/A
CAGR 5-Years
63%
CAGR 10-Years
5%
Eurofins-Cerep SA
PAR:ALECR
Pre-Tax Income
€8.7m
CAGR 3-Years
16%
CAGR 5-Years
20%
CAGR 10-Years
31%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Market Cap
17B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and maintaining a commitment to sustainability, Sartorius has built a reputation as a trusted partner in the industry, addressing the growing demand for effective therapies amidst an ever-evolving healthcare landscape. As the global biopharmaceutical market expands, driven by advancements in personalized medicine and precision therapies, Sartorius is well-positioned to capitalize on these trends. The company’s recent strategic acquisitions and investments in digitalization and automation enhance its product offerings, allowing clients to improve efficiencies and reduce time-to-market for essential therapeutics. Boasting a strong financial track record and a commitment to research and development, Sartorius Stedim Biotech SA not only ensures consistent growth but also aligns with long-term health sector trends. For investors, this combination of strategic vision, robust market position, and innovative capabilities makes Sartorius an attractive investment opportunity in the booming biotechnology sector.

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Pre-Tax Income?
Pre-Tax Income
236m EUR

Based on the financial report for Jun 30, 2024, Sartorius Stedim Biotech SA's Pre-Tax Income amounts to 236m EUR.

What is Sartorius Stedim Biotech SA's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
9%

Over the last year, the Pre-Tax Income growth was -71%. The average annual Pre-Tax Income growth rates for Sartorius Stedim Biotech SA have been -29% over the past three years , -6% over the past five years , and 9% over the past ten years .

Back to Top